Objective-Widespread death of implanted cells hampers stem cell therapy for acute myocardial infarction (AMI). Based on the pleiotropic beneficial effects of statins, we examined whether simvastatin (SIMV) increased the efficacy of mesenchymal stem cell (MSC) transplantation after AMI. Methods and Results-Chinese miniswine (nϭ28) were randomized to 1 of 4 groups (nϭ7 per group): control, SIMV (0.25 mg/kg ⅐ d), MSC transplantation, and SIMVϩMSCs. AMI was created by ligating the left anterior descending coronary artery; MSCs were injected immediately into the cyanotic myocardium. At 6 weeks, MRI showed the number of dyskinetic segments and the infarct size were significantly decreased in the SIMV group. Cardiac function improved and the perfusion defect decreased significantly in the SIMVϩMSC group but not in the MSC-only group (PϽ0.05, versus control group). MSC survival and differentiation were significantly better in the combination group than in the MSC-only group (PϽ0.01). Cell apoptosis decreased significantly in both the SIMV and the SIMVϩMSC groups but not in the MSC-only group when compared with controls (PϽ0.05). Furthermore, oxidative stress and inflammatory response was significantly reduced in the infarcted regions in both the SIMV and the SIMVϩMSCs groups. Conclusions-SIMV treatment improves the therapeutic efficacy of MSC transplantation in acutely infarcted hearts by promoting cell survival and cardiovascular differentiation.
C ellular cardiomyoplasty (CCM), or cell-based repair, is emerging as a potential novel therapy for acute myocardial infarction (AMI). CCM can help regenerate damaged cardiovascular tissue by implanting stem/progenitor cells or by mobilizing peripheral blood-or bone marrow-derived stem cells into the site of cardiac injury. [1] [2] [3] Among donor cell types used for CCM, bone marrow-derived mesenchymal stem cells (MSCs) have been the focus of much research because of their plasticity and availability. 4 However, the efficacy of cell-based therapy is hindered by the presence of proinflammatory and proapoptotic factors in the injured heart that increase cell death. Successful cellular therapy requires survival, proliferation, and differentiation of implanted stem cells. The in vivo fate of implanted cells is determined by many environmental factors. However, the most important factor in determining donor cell fate is the local postinfarction milieu of the myocardium. 5 As the most prescribed drug, statins have many cardioprotective effects independent of their lipid-lowering ability. Statins can protect endothelial function and the integrity of the microvasculature, increase nitric oxide bioavailability, exert antioxidant and antiinflammatory effects, and stabilize atherosclerotic plaques. 6 -10 Based on these beneficial effects of statins, this study tested whether simvastatin improves the fate of MSCs in vivo, thus further enhancing cardiac function.
Methods Animals
Ten-month-old domestic miniswine (30Ϯ5 kg) were obtained from the Laboratorial Animal Center of the Chinese University of Agriculture, China, or Texas A&M University (College Station, Tex). All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health, USA. Experimental procedures were approved by the Care of Experimental Animals Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College, China.
Domestic miniswine (nϭ28) were divided into 4 groups of 7 each: group 1 (control), group 2 (simvastatin administration only, SIMV), group 3 (transplantation of MSCs only), and group 4 (combination of simvastatin and MSC transplantation).
Other experimental procedures are listed in supplemental materials (available online at http://atvb.ahajournals.org).
Results
All the animals operated on survived to the end of the study except for 3 (1 in the control group, 1 in group SIMV, and 1 in group MSCs). Measurements were successfully obtained and analyzed from all the living animals. Phenotypic characterization showed that pig bone marrow-derived MSCs were negative for the CD34 and CD45 antigens but positive for CD29 (99.94Ϯ0.05%) and CD90 (97.43Ϯ1.29%; supplemental Figure I ). In MSCs labeled with DAPI, cell viability was consistent at about 98%, which is similar to that in control MSCs labeled without DAPI.
Statin Improves Morphology of Infarcted Myocardium With MSC Implantation
Hematoxylin and eosin ( Figure 1A ) and Masson trichrome staining ( Figure 1B ) showed the development of severe fibrosis and chronic inflammation with the infiltration of numerous leukocytes in the infarcted regions in control pigs and in those treated with MSCs only. In contrast, reduced fibrosis and inflammatory cell infiltration were seen in the hearts of the groups treated either with SIMV alone or with both SIMV and MSCs. ( Figure 1C and 1D).
Statin Enhances Survival and Myogenesis of Implanted MSCs
Immunofluorescent miscroscopy revealed higher numbers of DAPI-labeled cells in the hearts of pigs treated with SIMVϩMSCs than in pigs treated only with MSCs (310.6Ϯ83.8 versus 70.5Ϯ22.3, PϽ0.01; Figure 2A and 2E), indicating increased survival of implanted cells in postinfarction hearts treated with both SIMV and MSCs. Further immunofluorescent analyses showed that DAPI-labeled cells expressed cardiac-and vessel-specific proteins, including VWF and SM-actin ( Figure 2B ), ␣-sarcomeric actin ( Figure 2C ), and cardiac troponin T ( Figure 2D ), in the hearts of pigs treated with MSCs. The efficiency with which DAPI-labeled cells differentiated into cardiomyocytes was greater in the combination group than in the group treated only with MSCs (46.0Ϯ5.2% versus 9.6Ϯ3.5%, PϽ0.01; Figure 2F ). 
Statin Improves Cardiac Perfusion and Performance
Initial baseline SPECT at 1 week after cell transplantation demonstrated no significant differences among the 4 groups (Pϭ0.984). At end point, follow-up SPECT showed no significant changes in the reduction of perfusion defect in the MSC only group (52.2Ϯ16.3%, at baseline versus 49.8Ϯ13.6% at end point, dϭ2.3Ϯ4.1%) compared to that in the control group (50.7Ϯ14.5% at baseline versus 47.8Ϯ11.1% at end point, dϭ2.8Ϯ6.1%, PϾ0.05). However, significantly reduced defect was observed in both the SIMVtreated and combination groups compared with the control group (52.7Ϯ15.5% at baseline to 39.3Ϯ12.4% at end point dϭ13.3Ϯ6.2% [PϽ0.05] and 49.7Ϯ16.8% to 28.3Ϯ7.4% dϭ21.4Ϯ12.0% [PϽ0.01], respectively). There was no obvious synergy in restoring perfusion between SIMV and MSCs (Pϭ0.192; Figure 3 ).
At baseline, no significant differences in MRI parameters were found among the groups. At end point, the combination group showed significantly improved left ventricular ejection fraction (LVEF). The average increase in LVEF was about 6.5Ϯ4.4% (PϽ0.01) compared to that in the control group. The change in end-diastolic volume (EDV) was not significantly different among the 4 groups (Pϭ0.846); the change in end-systolic volume (ESV) was significant only in comparison between the combination group and the control group (PϽ0.05), indicating that the systolic function of the left ventricle was significantly improved by MSC transplantation facilitated by SIMV administration. The size of the infarct region was reduced in both the SIMV group and the combination group compared with the control group (PϽ0.01), and the number of dyskinetic segments was lower in both the SIMV and combination groups than in the control group (PϽ0.05, respectively). Wall thickening significantly increased only in the combination group compared with the control group (PϽ0.01; Table) . A synergism appeared to occur between SIMV and MSCs, in the infarcted area (interaction term Pϭ0.001), dyskinetic segments (interaction term Pϭ0.021), and wall thickening (interaction term Pϭ0.000).
Statin Inhibits Apoptosis in the Periinfarct Myocardium
Analysis of the heart sections by TUNEL ( Figure 4A ) indicated significantly fewer apoptotic myocytes in the infarcted left ventricles of SIMV-treated pigs (both SIMV only and the combination groups) than in the left ventricles of controls (apoptotic index, 5.6Ϯ1.5 in the SIMV group, 2.3Ϯ0.3 in the combination group, and 10.1Ϯ1.8 in the control group, respectively; PϽ0.01). Furthermore, the apoptotic index was significantly lower in the combination group than in the SIMV group (PϽ0.01; Figure 4B ). However, the apoptotic index in the MSC only group (9.2Ϯ1.4) did not differ significantly from that in the control group (Pϭ0.262). In addition, Western blot analysis indicated that the proapoptotic protein, Bax, was significantly increased in the control group compared with sham animals at end point (PϽ0.01). However, SIMV treatment significantly decreased Bax expression in the SIMV group and combination group when compared with control animals (PϽ0.01). In contrast, MSC transplantation alone did not decrease Bax levels significantly (Pϭ0.069). Levels of the antiapoptotic protein, Bcl-2, were lower in control animals than in the sham group (PϽ0.05), but Bcl-2 was upregulated by statin treatment and MSC transplantation in the SIMV, MSC only, and combination groups (PϽ0.0001).
Statin Treatment Reduces Oxidative Stress
At the end point, SOD activity in the postinfarction myocardium was significantly higher in the SIMV and combination groups than in the control group (100.8Ϯ12.1, 108.5Ϯ10.2, and 83.4Ϯ8.8 U/mg protein, respectively, PϽ0.05), indicating that statin administration enhanced the ability to scavenge free radicals in the postinfarction myocardium. However, there was not a significant difference between the control group and the MSC only group (87.4Ϯ10.2 U/mg protein, Pϭ0.515). In contrast, the MDA content of the myocardium was lower in the SIMV and combination groups than in the control group (5.8Ϯ0.7, 5.6Ϯ0.9, and 9.0Ϯ0.8 nmol/mg protein, respectively; PϽ0.01), suggesting statin treatment reduced lipid peroxidation and subsequent cell damage. MDA content did not differ significantly between the control and the MSC only groups.
Statin Treatment Reduces Expression of Proinflammatory Cytokines
Increased expression of IL-1, IL-6, and TNF-␣ was found in the postinfarction myocardium of the control group compared with sham animals (PϽ0.01), whereas ␤-actin levels remained unchanged ( Figure 5A ). However, SIMV treatment reduced the induction of IL-1␤, IL-6, and TNF-␣ in the SIMV group (PϽ0.01) and the combination group (PϽ0.01) when compared with the control group. In addition, MSC transplantation alone decreased the levels of IL-1␤ ( Figure 5B ) and IL-6 ( Figure 5C ) compared with control (PϽ0.01) but exerted no significant effect on TNF-␣ expression ( Figure  5D ). These data indicate that combined treatment with SIMV and MSCs reduces the inflammatory response in the myocardium after AMI.
Discussion
Bone marrow-derived MSCs colonizing the myocardium may differentiate into resident cells in the hearts, including cardiomyocytes. 11 The repair process of the postinfarction heart is complicated and dynamic, and the local microenvironment differs at various time points after infarction. Thus, the milieu for implanted cells differs, depending on the time of injection. Li and collegues 5 reported that the effects of cell transplantation on scar expansion and cardiac function were better when cells were injected 2 weeks after cryoinjury than when injected immediately or 4 weeks after injury. They proposed that excessive cell death caused by early postinfarction inflammation hinders improvement in remodeling or function. To achieve benefits, the donor cells should engraft in the targeted region and survive. In our study, most of the implanted MSCs did not survive in the postinfarction myocardium, indicating that the local environment just after AMI and reperfusion was unsuitable for MSC engraftment. Moreover, our study indicates that the mechanisms resulting in MSC death may include inflammation, oxidative stress, apoptosis, and ischemia/reperfusion. It is unclear why MSC transplantation alone decreased IL 1-␤ and increased Bcl-2 expression in the postinfarction myocardium but did not produce functional benefits. In our study, low-dose short-term administration of simvastatin around the time of infarction and reperfusion decreased the number of dyskinetic segments as detected by MRI and reduced the area of perfusion defect as seen on SPECT. These findings are consistent with those from previous reports of statins in experimental myocardial infarction. 12 Statins may provide benefits after AMI and reperfusion via multiple mechanisms, including antiinflammatory and antioxidative stress reactions. [13] [14] [15] We found that simvastatin administration alone did not increase capillary density in or around the infarcted region; therefore, under experimental conditions in the porcine model, treatment with simvastatin alone provides limited benefits in terms of angiogenesis (supplemental Figure II) . In a study in mice with permanent ligation of the LAD arteries, low-dose simvastatin (0.25 mg/kg.d) administered for 28 days after infarction improved survival and cardiac function and inhibited cardiac hypertrophy and pulmonary edema. 16 Moreover, in a previous study, we found that pretreatment with simvastatin decreased the area at risk after AMI and reperfusion by activating ATP-sensitive potassium channels. 6, 17 Our current study provides evidence of the multiple benefits of simvastatin and suggests that statin administration may improve the local milieu after AMI and reperfusion.
Perhaps the most important finding in our study is that simvastatin treatment may significantly increase the in vivo survival and differentiation of implanted cells in the myocardium after infarction over that seen with MSC transplantation alone. Furthermore, simvastatin treatment appears to provide significant benefits in cardiac function, indicating that stem cell engraftment, survival, and differentiation are enhanced in our experimental model.
A previous study showed that DAPI that was released from labeled cells that had been killed by heat would falsely stain other unlabeled cells. 18 However, the in vitro conditions of that study differ from those found in vivo and do not represent the environment in which implanted MSCs survived. In addition, there have not been other studies until now that have shown that DAPI was taken up by host cells, after DAPI-labeled MSCs were implanted in vivo. Furthermore, in our study, if DAPI that was released from dead or mitotic implanted MSCs falsely labeled host cardiomyocytes, then the total number of DAPI-positive cells would not differ significantly between groups because we implanted the same number of cells (3ϫ10 7 MSCs per animal) in all animals in the MSC and combination groups. However, our results showed significant differences between the 2 implantation groups. Based on these findings, we believe that the difference in the DAPI-positive cell numbers between the 2 groups resulted from the different survival potential of the implanted MSCs. Detecting the mitotic potential of stem cells after their implantation in infarcted myocardium is important, as is determining the impact of mitosis on DAPI labeling. However, visualizing or determining cell mitosis in cardiac or other tissue is technically difficult because of the limited capability of tracking cells.
Our findings indicate that the local milieu plays a critical role in cell engraftment. Although the usefulness of stem cells for cardiac repair has been examined in clinical studies, progress in cellular cardiomyoplasty is hampered by the poor survival of implanted cells. A high proportion of engrafted cells die after implantation in injured hearts. 19, 20 Our results suggest that the molecular mechanisms of stem cell death in acutely ischemic hearts include apoptosis, oxidative stress, and inflammation in the postinfarction myocardium, a finding supported by previous studies. 5, 21 Protecting grafted cells from acute death in ischemic myocardium is important for clinical applications. To date, several methods have been used to improve the fate of implanted cells, such as heat-shock treatment, 22 Akt-engineering, 23 and overexpression of hemeoxygenase-1. 24 We believe that intervention aimed at improving the quality of the local microenvironment may improve survival and facilitate the biological behavior of implanted cells.
In the present study, low-dose simvastatin alone did not produce detectable benefits in cardiac function, except for a possible decrease in infarcted area; however, it significantly increased the potential of survival and differentiation of implanted MSCs. Many studies including our own work have shown that inflammatory cytokines can induce apoptosis of cardiovascular cells. 25 During AMI, myocytes are exposed to a variety of proinflammatory and proapoptotic factors, and ultimately undergo high degrees of apoptosis. The statin-mediated reduction in inflammatory cytokines may therefore improve survival of both implanted MSCs and resident cardiovascular cells in the infarcted hearts. The beneficial effect can be further enhanced by the statin-mediated inhibition of expression of the proapoptotic protein Bax or increase in the expression of the antiapoptotic protein Bcl-2. However, Bax and Bcl-2 are not the only apoptosis regulation factors that could explain our findings in the TUNEL assay. Previous studies have indicated that the mechanisms of the statininduced inhibition of cellular apoptosis may include activation of the PI3K/Akt/eNOS/NO pathway, the inhibition of glycogen synthesis kinase 3␤ to stabilize ␤-catenin, and antioxidative stress. 26 -28 Reactive oxygen species (ROS) contribute to cardiomyocyte apoptosis and inflammation, especially under the conditions of AMI. 29 After AMI, ROS can activate nuclear factor kappa B, which then triggers gene expression of proinflammatory cytokines, such as TNF-␣ and interleukins, and initiates inflammatory reactions. 30 Several studies have shown that antioxidant treatment reduces infarct size in the rat AMI model. 31, 32 The acute release of large amounts of ROS has been implicated in the cell death associated with AMI, whereas the chronic release of ROS may contribute to the development of left ventricular hypertrophy and heart failure. 33, 34 Antioxidant treatment appears to attenuate cardiac fibrosis. 35 Our results indicate that simvastatin administration may inhibit the oxidative stress level in the infarcted myocardium during the chronic stage, which is consistent with previous findings. Nonetheless, we have not fully defined the precise signaling pathway by which SOD and MDA regulate tissue repair and regeneration.
In conclusion, our study has provided in vivo evidence showing that short-term administration of low-dose simvastatin may increase the efficacy of cellular cardiomyoplasty and improve cardiac function after MSC transplantation.
